Skip to main content

Table 3 Characteristics of patients at baseline and after 6 months of treatment

From: Effects of a new nutraceutical combination on cognitive function in hypertensive patients

  Baseline 6-months Treatment effecta
MoCA test ES    
 Control group 1.94 ± 0.94 1.83 ± 0.79 <0.001
 Active treatment group 1.89 ± 1.08 2.89 ± 1.08
Word Match Testing ES    
 Control group 2.00 ± 0.97 1.72 ± 0.89 0.023
 Active treatment group 2.50 ± 1.20 2.94 ± 1.21
Stroop test E ES    
 Control group 2.22 ± 0.88 1.94 ± 1.11 0.050
 Active treatment group 1.67 ± 1.65 2.00 ± 1.41
Stroop test T ES    
 Control group 2.67 ± 0.91 2.22 ± 1.11 0.124
 Active treatment group 2.28 ± 1.67 2.61 ± 1.42
EQ-VAS    
 Control group 65.3 ± 12.8 63.6 ± 12.3 <0.001
 Active treatment group 68.1 ± 12.8 80.6 ± 12.0
  1. Values are means ± standard deviation
  2. MoCa = Montreal Cognitive Assessment; ES = equivalent score; EQ-VAS = EQ-5D test visual analogue scale
  3. a = active treatment versus placebo, GLM analysis